User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8121

Interactions with Platform & by Email *

INTERACTIONS

1137

Unique # Participated *

PARTICIPANTS

244

Responses Validated *

VALIDATIONS

46

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Global Pharmaceutical Industry Hit by Economic Downturn.....II-1
Credit Crunch to Affect Biological Drug Pipeline.....II-1
Biotech Bankruptcies Rife in the Current Economic Downturn.....II-1
1$100
   Economic Downturn Takes Toll on R&D.....II-2
Autoimmune Disease Therapeutics – An Ever Flourishing Market.....II-2
Rheumatoid Arthritis – A Chronic, Debilitating Disease.....II-2
1$100
   Incidence and Prevalence Higher in Urban and Developed Regions.....II-3
Rheumatoid Arthritis - Market Overview.....II-3
1$100
   A Look At Arthritis Market Sales Data.....II-4
Table 1: World Arthritis Market - Value Sales of Drug Classes for 2006 and 2007 (USD billion) (includes corresponding Graph/Chart).....II-4

Table 2: World Arthritis Market - Value Sales of Anti-TNF Biologics for 2007 (USD billion) (includes corresponding Graph/Chart).....II-4

Table 3: World Arthritis Market - Value Sales of Select NSAIDs for 2007 (USD billion) (includes corresponding Graph/Chart).....II-4
1$350
   Table 4: World Arthritis Market - Value Sales of COX-2 Inhibitors for 2007 (USD billion).....II-5
Market Outlook.....II-5
Global Market Estimates and Forecasts.....II-5
2$350
   Anti-TNF Biologic Therapies – The Market Leading RA Drugs.....II-7
Table 5: World Rheumatoid Arthritis Market - Value Sales of Biologic Response Modifiers: 2007 and 2008 (in US$ Billion) (includes corresponding Graph/Chart).....II-7
1$350
   Biologics Continue to Gain Market Share.....II-8
Expensive Biologics to Drive Value Growth.....II-8
Year of Approval of Leading Biologics in Rheumatoid Arthritis Therapy.....II-8
New Products to Drive Market Growth.....II-8
1$100
   Superior Outcomes to Enhance Adoption of Biologics.....II-9
Efficacy and Convenience – Key Factors Driving Physician’s Decision.....II-9
Non-Anti-TNFs, Orencia to Gain Strength.....II-9
Patent Expiry – A Mid- to Long-term Threat.....II-9
1$100
   Year of Expected Generic Market Entry of Leading Biologics in Rheumatoid Arthritis
  Therapy.....II-10
Competitive Landscape.....II-10
1$100
   Table 6: Comparative Analysis of Leading Biologic Rheumatoid Arthritis Drugs based on ACR Scores by End Point (includes corresponding Graph/Chart).....II-111$350
   High Prices and Safety Concerns.....II-121$100
   Arthritis.....II-13
Rheumatoid Arthritis.....II-13
The Disease Progression.....II-13
The Age Factor.....II-13
1$100
   Causes and Diagnosis.....II-14
Signs and Symptoms.....II-14
Treatment.....II-14
1$100
   Non-steroidal Anti-inflammatory Drugs.....II-15
Side Effects Profile.....II-15
Cyclo-Oxygenase-2 Inhibitors.....II-15
1$100
   Celecoxib.....II-16
Others.....II-16
Anti-rheumatic Steroids.....II-16
1$100
   Side Effects Profile.....II-17
Corticosteroids.....II-17
Glucocorticoids.....II-17
Disease-modifying Anti-rheumatic Drugs (DMARDs).....II-17
1$100
   D-penicillamine.....II-18
Gold Salts.....II-18
Hydroxychloroquine.....II-18
Leflunomide.....II-18
Methotrexate.....II-18
Sulfasalazine.....II-18
Others.....II-18
1$100
   Biological Response Modifiers.....II-19
Adalimumab (Humira).....II-19
1$100
   Etanercept.....II-201$100
   Infliximab.....II-21
Anakinra.....II-21
1$100
   Abatacept.....II-221$100
   Rituximab.....II-231$100
   Tocilizumab.....II-241$100
   The Rheumatoid Arthritis Pipeline.....II-25
List of Select RA Drug Candidates in Various Clinical Pipeline Phases:
  2008-09.....II-25
1$100
   Opportunities Aplenty for New Oral Agents in RA Treatment.....II-262$200
   Velcura to Commence Clinical Trials for Lead Rheumatoid Arthritis Compound.....II-28
Biogen Announces Phase II Trial Results for Baminercept in Rheumatoid
  Arthritis.....II-28
Genentech, Biogen Announce Encouraging Phase III Results of Rituxan.....II-28
1$100
   Chelsea Announces Encouraging Preclinical Results for RA Drug Candidate.....II-29
Medarex Commences Phase II Trials for Rheumatoid Arthritis Treatment Drug.....II-29
ChemoCentryx Launches Phase I Clinical Trial for CCR1 Inhibitor.....II-29
Chelsea Commences Phase II Trial for CH-1504.....II-29
Arana Therapeutics Initiates Phase II Trial of ART621 in Rheumatoid Arthritis.....II-29
1$100
   VGX Pharma Initiates Follow-on Phase I Study for VGX-1027.....II-30
Genmab to Commence Phase I/II Trial of Ofatumumab in RA Patients.....II-30
Can-Fite Announces Seikagaku’s Proposed Phase I Trial for CF101 in Japan.....II-30
Hollis-Eden Pharma Initiates Phase I/II Trial of Triolex in RA Patients.....II-30
Trubion Pharma Announces Initiation of Phase 1 Trial of SBI-087.....II-30
1$100
   Micromet and Nycomed Initiate Formal Preclinical Safety Studies.....II-311$100
   GlaxoSmithKline Forms Strategic Alliance with Archemix.....II-32
Cypress Bioscience Acquires Proprius Pharmaceuticals.....II-32
1$100
   Biotie to Takeover German Company, elbion.....II-33
Roche to Acquire UK Company, Piramed.....II-33
Pipex Acquires Rheumatoid Arthritis Drug Candidate, dnaJP1.....II-33
1$100
   Latona Signs Two Agreements to Acquire Orphan Drug Status and Patent Rights.....II-34
MorphoSys, Galapagos Sign Alliance to Co-Develop Antibody Therapies.....II-34
1$100
   Nycomed Inks Agreement with Immunomedics for Veltuzumab.....II-35
Affitech Signs Antibody Discovery and Development Deal with Omeros.....II-35
1$100
   Entelos Signs Research Agreement with UCB Pharma.....II-36
Novo Nordisk and VLST Form Partnership to Develop Therapeutic Targets.....II-36
Maxygen Enters into Agreement with Astellas for MAXY-4.....II-36
1$100
   GlaxoSmithKline Forms Global Alliance with Regulus Therapeutics.....II-37
Can-Fite Signs License Agreement with Korean Company for RA Drug.....II-37
1$100
   Amgen, Wyeth Announce U.S. Prescribing Information Update for Enbrel.....II-38
Galapagos Secures Grant for Rheumatoid Arthritis Drug Development.....II-38
MorphoSys and University of Melbourne to Receive U.S. Patent.....II-38
Merrimack Acquires Funds for Developing Biologics.....II-38
1$100
   Galapagos Announces GT146 Milestone Achievement.....II-39
Amgen Acquires Avidia.....II-39
Iroko Acquires Two Pharmaceutical Products from Merck.....II-39
1$100
   EvoGenix to Merge with Peptech.....II-40
Eli Lilly and MacroGenics Tie Up for Developing Teplizumab.....II-40
1$100
   Pharmacopeia and Wyeth Sign R&D Agreement to Develop JAK3 Inhibitors.....II-41
Nuon Enters into Strategic Agreement with Kissei Pharmaceutical.....II-41
Roche and Toyama Enter into Licensing Agreement for T-5224.....II-41
1$100
   GSK and Genmab Sign Partnership Agreement for HuMaxCD20.....II-421$100
   UCB Receives FDA Approval for Cimzia for Treating Rheumatoid Arthritis.....II-43
Centocor Announces FDA Approval of Simponi™ for Rheumatoid Arthritis.....II-43
Chugai Announces Japanese Approval of Actemra for RA Treatment.....II-43
1$100
   Abbott Secures Japanese Approval for Humira for RA Treatment.....II-44
Chugai and Roche Secure Swiss Approval for RoACTEMRA.....II-44
Chugai and Roche Announce Further FDA Guidance on BLA for Actemra.....II-44
Roche, Chugai Announce CHMP’s Positive Recommendation for RoActemra.....II-44
1$100
   Roche’s Actemra Recommended for Approval by FDA Advisory Committee.....II-45
Centocor, Schering-Plough Submit MAA for Golimumab Approval.....II-45
UCB Submits MAA to the EMEA for Approval of Certolizumab Pegol.....II-45
1$100
   Abbott Secures FDA Approval for Humira for Polyarticular JIA Treatment.....II-46
Xian-Janssen Introduces Remicade, Branded infliximab in China.....II-46
Abbott Files for Humira Approval as JRA Treatment in the US and Europe.....II-46
Roche Receives NICE Approval for MabThera as Severe RA Treatment.....II-46
1$100
   Abbott Laboratories, Inc. (USA).....II-47
Amgen, Inc. (USA).....II-47
1$100
   Biogen Idec, Inc. (USA).....II-481$100
   Bristol-Myers Squibb Company (USA).....II-491$100
   F. Hoffmann-La Roche AG (Switzerland).....II-50
Chugai Pharmaceutical Co., Ltd. (Japan) – A Member of Roche Group.....II-50
1$100
   Genentech Inc. (USA).....II-511$100
   Genmab AS (Denmark).....II-52
GlaxoSmithKline PLC (UK).....II-52
1$100
   Johnson & Johnson Services, Inc. (USA).....II-53
Schering-Plough Corp. (USA).....II-53
1$100
   UCB S.A. (Belgium).....II-54
Wyeth (USA).....II-54
2$125
   Table 7: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region - US, Japan, Europe, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-561$350
   Table 8: World 10-Year Perspective for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region - Percentage Breakdown of Dollar Revenues for the US, Japan, Europe, Latin America and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-571$350
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
Rheumatoid Arthritis – Prevalence.....III-1
Table 9: US Rheumatoid Arthritis Patient Group Breakdown for 2008 (includes corresponding Graph/Chart).....III-1
1$200
   Table 10: US Moderate to Severe Rheumatoid Arthritis Patient Group Breakdown by Therapy for 2008 (includes corresponding Graph/Chart).....III-2
Market Overview.....III-2
1$200
   Market Trends.....III-3
Biologic Drugs Lead the Fray.....III-3
Table 11: US Rheumatoid Arthritis Therapeutics Market - Value Sales of Leading Biologic Therapies for 2007 (includes corresponding Graph/Chart).....III-3
1$200
   Enbrel and Humira Continue to Gain Share in the Anti-TNF Market.....III-4
Research and Development.....III-4
2$125
   Strategic Corporate Developments.....III-64$175
   Product Approvals.....III-102$125
   Select Players.....III-126$275
   B. Market Analytics.....III-18
Table 12: US Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) - Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-18
1$200
   A. Market Analysis.....III-19
Current & Future Analysis.....III-19
Market Overview.....III-19
Table 13: Japanese Rheumatoid Arthritis Patient Group Breakdown for 2008 (includes corresponding Graph/Chart).....III-19
1$200
   Research and Development.....III-20
Strategic Corporate Developments.....III-20
1$75
   Product Approvals.....III-211$75
   Select Player.....III-221$75
   B. Market Analytics.....III-23
Table 14: Japanese Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) - Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-23
1$200
   A. Market Analysis.....III-24
Current & Future Analysis.....III-24
Rheumatoid Arthritis – Prevalence.....III-24
Table 15: European Rheumatoid Arthritis Patient Group Breakdown for 2008 (includes corresponding Graph/Chart).....III-24
1$200
   Market Overview.....III-25
Research and Development.....III-25
Strategic Corporate Developments.....III-25
5$225
   Product Approvals.....III-301$75
   Select Players.....III-313$175
   B. Market Analytics.....III-34
Table 16: European Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) - Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-34
1$200
   A. Market Analysis.....III-35
Current & Future Analysis.....III-35
B. Market Analytics.....III-35
Table 17: Latin American Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-35
1$200
   Table 18: Latin American 10-Year Perspective for Rheumatoid Arthritis Therapeutics by Region - Percentage Breakdown of Dollar Revenue for Brazil and Rest of Latin America Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-361$200
   A. Market Analysis.....III-37
Current & Future Analysis.....III-37
Canada.....III-37
Canadian Rheumatoid Arthritis Therapeutics Market.....III-37
Australia.....III-37
Overview of Rheumatoid Arthritis in Australia.....III-37
1$75
   Table 19: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Age Group (includes corresponding Graph/Chart).....III-38

Table 20: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Gender (includes corresponding Graph/Chart).....III-38
1$200
   Research and Development.....III-39
Strategic Corporate Developments.....III-39
1$75
   Product Launch.....III-40
B. Market Analytics.....III-40
Table 21: Rest of World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) - Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-40
1$200